Role of miRNA in Lung Cancer-Potential Biomarkers and Therapies

Author(s): Xiaohong Du, Jitai Zhang, Juping Wang*, Xiaoming Lin*, Feng Ding*.

Journal Name: Current Pharmaceutical Design

Volume 23 , Issue 39 , 2017

Submit Manuscript
Submit Proposal

Abstract:

MicroRNAs (miRNAs) are small noncoding RNAs, which downregulate gene expression by repressing or degrading mRNA targets. Lung cancer (LC), together with liver and colorectal cancers are the three leading causes of cancer death worldwide, and 80% of LCs belong to non-small cell lung cancers (NSCLCs). Despite a great advancement in developing distinct and delicate tools for early diagnosis and targeted therapies over the last decade, only about 15% of the NSCLC patients eventually survived. MiRNAs are frequently dysregulated in carcinoma, including LC. Numerous lines of evidence have demonstrated various roles played by miRNAs in the development and progression of LC. In this review, we propose to summarize the current understanding of miRNAs in LC, with a particular focus on translational application of miRNAs as novel diagnostic and prognostic biomarkers and tools for treatment.

Keywords: miRNA, lung cancer, biomarker, non-small cell lung cancer, squamous cell carcinoma, adenocarcinoma, exosome.

Rights & PermissionsPrintExport Cite as


Article Details

VOLUME: 23
ISSUE: 39
Year: 2017
Page: [5997 - 6010]
Pages: 14
DOI: 10.2174/1381612823666170714150118
Price: $58

Article Metrics

PDF: 16
HTML: 2